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Available online 26 February 2016The accurate identiﬁcation of glioblastoma progression remains an unmet clinical need. The aim of this prospec-
tive single-institutional study is to determine and validate thresholds for themainmetabolite concentrations ob-
tained by MR spectroscopy (MRS) and the values of the apparent diffusion coefﬁcient (ADC) to enable
distinguishing tumor recurrence from pseudoprogression. Thirty-nine patients after the standard treatment of
a glioblastoma underwent advanced imaging by MRS and ADC at the time of suspected recurrence — median
time to progression was 6.7 months. The highest signiﬁcant sensitivity and speciﬁcity to call the glioblastoma re-
currencewas observed for the total choline (tCho) to total N-acetylaspartate (tNAA) concentration ratiowith the
threshold ≥1.3 (sensitivity 100.0% and speciﬁcity 94.7%). The ADCmean value higher than 1313 × 10−6 mm2/s
was associated with the pseudoprogression (sensitivity 98.3%, speciﬁcity 100.0%). The combination of MRS fo-
cused on the tCho/tNAA concentration ratio and the ADCmean value represents imaging methods applicable to
early non-invasive differentiation between a glioblastoma recurrence and a pseudoprogression. However, the in-
stitutional deﬁnition and validation of thresholds for differential diagnostics is needed for the elimination of
setup errors before implementation of these multimodal imaging techniques into clinical practice, as well as
into clinical trials.






Apparent diffusion coefﬁcient1. Introduction
The critical biological characteristic of a glioblastoma (GBM), the
most frequent and serious primary brain tumor in adults is an inevitable
progression after standard therapy with the median of 6.9 months
(Dusek et al., 2014; Stupp et al., 2005). Tumor recurrence develops in al-
most all patients despite the aggressive standard ﬁrst line treatment,
which comprised of radiotherapy and temozolomide usage (RT and
TMZ) (Stupp et al., 2005). GBM recurrence, however, has often similar
radiologic characteristics on conventional MRI as therapy-relatedy, St. Anne's University Hospital
.
. This is an open access article underchanges, like a pseudoprogression (PsP). Thus, the early and accurate di-
agnosis of GBM relapse constitutes to be an important clinical need, es-
pecially when more and more potentially active drugs are currently
being investigated for salvage treatment.
In comparison with standard structural MRI techniques, advanced
imaging methods, such as diffusion-weighted imaging (DWI) with ap-
parent diffusion coefﬁcient (ADC) mapping, and the proton MR spec-
troscopy (MRS), allow much deeper and still non-invasive insight into
the interpretation of brain lesions, resulting in greater speciﬁcity of di-
agnostic imaging (Ahmed et al., 2014; Bulik et al., 2015; Kao et al.,
2013; Roy et al., 2013). In our previous report of the consecutive series
of 24 patients with GBM, we described signiﬁcant differences in ADC
and MRS data between those with GBM relapse and PsP after standard
RT and TMZ treatment (Bulik et al., 2015). However, thresholds withthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Basic characteristics of the study cohort: T = temporal, F = frontal, P = parietal, O =
occipital, F–P = frontoparietal, 3D-CRT = Three-Dimensional Conformal Radiotherapy,
IMRT = Intensity-Modulated Radiotherapy.





Age at initial diagnosis (years)
Median 51 54 0.7
Range 29–66 35–64
Sex (n)
Men 28 (72%) 10 (63%) 0.5
GBM location (%)
T/F/P/O/F-P 38/29/19/5/9 34/31/14/7/14 0.7
Radiotherapy
Median dose (Gy) 60 60 0.9
Technique 3D-CRT/IMRT (%) 30/70 40/60 0.8
Cycles of adjuvant TMZ
Median 6 6 0.9
Range 1–12 4–10
Time to graphic progression (months)
Median (95% CI) 6.7 (2.9–9.6) 6.1 (4.8–8.8) 0.8
Diagnosis validation
Biopsy/subsequent imaging (%) 67/33 75/25 0.6
Final diagnosis
Tumor recurrence 29 (75%) 12 (75%) 1
Pseudoprogression 10 (25%) 4 (25%)
Overall survival (months)
Median (95% CI) 14.5 (12.9–17.4) 14.0 (13.1–15.2) 0.8
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quired before these methods can be implemented into our institutional
imaging protocols on a routine basis and used in the decision-making
process. In this report, we present our ﬁnal results of this prospective
study with extended number of patients, as well as the results from an
independent retrospective intra-institutional validation.
2. Methods
2.1. Characteristics of patients
Patients suitable for this study included the ones with histologically
proven GBM after gross total resection, as stated by an early post-
surgery MRI examination, who underwent the standard adjuvant treat-
ment consisting of concurrent RT (dose 60 Gy) and TMZ followed by ad-
juvant TMZ alone (Stupp et al., 2009). The standard follow-up imaging
protocol at our institution is the classic structural MRI after 6 weeks
and every 3 months thereafter. Patients were eligible for study enroll-
ment when suspected radiographic progression on the structural MRI
was found based on the neuro-radiologist's discretion. After they signed
an informed consent, the patients underwent the investigational ad-
vancedMRI, namelyMRS andDWI. The ﬁnal evidence of the disease sta-
tus was realized by means of biopsy/resection or early repeated
structural MRI depending on the clinical situation, patient's perfor-
mance status, de facto his or her best interest. The advanced imaging
protocol was approved by the Institutional Review Board of the St.
Anne's University Hospital Brno. Patients previously described in our
initial analysis are also included in the current study cohort (Bulik
et al., 2015). The validation cohort consisted of the independent series
of previous patients with GBM treated by surgery and adjuvant RT and
TMZ, who underwent MRS and DWI/ADC exams according to the
same protocol. Initially, the derived thresholds for pertinent MRS spec-
tra and ADCmean values were subsequently applied to predict a GBM
recurrence or treatment related changes, such as PsP and radionecrosis.
2.2. MR data acquisition
The advanced MRI examination was performed at 3.0T clinical MR
scanner (GE Medical Systems Discovery MR750), following the same
setup parameters as in our initial report (Bulik et al., 2015). MRSwas fo-
cused on gadolinium-enhanced lesions suspected of recurrence by
means of the chemical shift imaging (CSI) technique in two orthogonal
planes respecting the long axis of the lesion and the proximity to struc-
tures increasing noise in MR spectra (point-resolved spectroscopy se-
quence — PRESS, TR/TE 1800/144 ms, 16-cm FOV, 15-mm slice
thickness, and voxel size 10 × 10 × 15 mm3). Automatic prescanning
was performed prior to each spectroscopic scan to ensure adequate
water suppression. The MR spectra of all measured voxels were auto-
matically post-processed for each patient by LCModel version 6.3
(Provencher, 2001). The output of MRS processing by LCModel were
the concentrations of N-acetylaspartate and N-acetylaspartylglutamate
(tNAA), choline-containing compounds (tCho), total creatine (tCr),
lipids at 0.9–1.3 ppm, and lactate (Lac). Afterwards, the ratios of theme-
tabolite concentrations (tCho/tNAA, tCho/tCr, tNAA/tCr, Lac + Lip1.3/
tCr, Lac + Lip0.9–1.3/tCr) were calculated and visualized by jSIPRO 1.0
beta version (Jiru et al., 2013). The signal-to-noise ratio for each MR
spectrum and an errormap showing the error in ameasured concentra-
tion for each metabolite were calculated by using the jSIPRO software.
The concept of error images in jSIPRO was developed to help rejection
of low quality spectra (Jiru et al., 2006). From the voxels covering
gadolinium-enhancing region, these with the signal-to-noise ratio N 3
and the error of measured metabolite concentrations b20% where se-
lected and arranged based on the value of the Cho/NAA ratio. The voxels
with the highest Cho/NAA ratio were selected for further analyses.
An axial echo planar SE sequence (TR/TE 6000/100 ms), 5-mm slice
thickness, and diffusion gradient encoding in three orthogonaldirections (b = 0 and 1000 mm2/s, and 240-mm FOV) were utilized
for DWI imaging. ADC maps were calculated using the OsiriX software
version 6.0.2 64-bit (Pixmeo SARL, Switzerland) with the ADCMap Cal-
culation plugin version 1.9 (Stanford University). The mean ADC value
(ADCmean) of the voxel corresponding to the measured MRS voxel
was calculated.2.3. Data analysis
The optimal diagnostic cut-offs and the description of their sensitiv-
ity and speciﬁcity for the ﬁnal diagnosis of recurrence were derived
from the receiver operating characteristic (ROC) analysis with the area
under the ROC curve (AUC) for distinguishing between the two diag-
nostic groups (GBM relapse and PsP). Fisher's exact test for categorical
data and Mann–Whitney U test for continuous variables were used to
estimate the signiﬁcance of measured differences. Censoring the pa-
tients who were lost for the follow up, the overall survival was deﬁned
as the time elapsed between the GBM diagnosis and death from any
cause. The time to progression was measured since the end of RT and
TMZ with suspected progression at structural MRI as the event of inter-
est. The probability value p b 0.05was considered statistically signiﬁcant
in all tests. All statistical evaluations were performed using the statisti-
cal software Statistica 12 (StatSoft, Inc.).3. Results
3.1. Study patient characteristics
BetweenMay2013 andMarch 2015, the total of 39 patients (median
age 51, 72% men) with suspected GBM progression on the structural
MRIwas prospectively included into this study. The basic characteristics
of patients are summarized in Table 1. The median time to suspected
progression and the median overall survival were 6.7 months (95% CI
2.9–9.6) and 14.5 months (95% CI 12.9–17.4), respectively. The ﬁnal di-
agnosis was established by a biopsy in 26 patients (67%) and by follow-
up imaging in 13 patients (33%). The diagnosis of a GBM recurrence
yielded in 29 patients (75%) with the rest having PsP. No case of
radionecrosis was found in our cohort of patients.
Table 2
Calculated cut-offs for the diagnosis of a tumor recurrence with related sensitivity and speciﬁcity for themost important concentration ratios of themetabolitesmeasured byMRS and for
ADCmean.
Metabolite AUC (95% CI) p Cut-off for recurrence Sensitivity Speciﬁcity
tCho/tNAA 0.993 (0.978; 1.000) b0.001 ≥1.3 100.0 94.7
tCho/tCr 0.691 (0.539; 0.843) 0.013 ≥0.7 74.6 63.2
tNAA/tCr 0.949 (0.873; 1.000) b0.001 ≤0.7 96.6 94.7
Lac + Lip 1.3/tCr 0.714 (0.559; 0.868) 0.003 ≥1.6 76.3 68.4
Lac + Lip 0.9–1.3/tCr 0.723 (0.568; 0.879) 0.004 ≥2.0 78.0 68.4
ADCmean [10−6 mm2/s] 0.998 (0.993; 1.000) b0.001 ≤1313 98.3 100.0
318 T. Kazda et al. / NeuroImage: Clinical 11 (2016) 316–3213.2. Advanced imaging characteristics
The values of metabolite concentration ratios are summarized in
Table 2, the percentage distribution of patients in Table 3, and typical
imaging ﬁndings are presented in Fig. 1. The mean and standard devia-
tion of the signal-to-noise ratios of MR spectra in the analyzed voxels
was 4.75± 0.80. The average number of voxels with acceptable spectra
quality per patient was 3.75 ± 1.13 and varied based on the proximity
of the skull and a resection cavity as the most signiﬁcant noise-
conducting factors.
A signiﬁcant difference in the tCho/tNAA and tNAA/tCr ratios was
found between the GBM relapse and PsP. The GBM relapse was charac-
terized by the tCho/tNAA ratio ≥ 1.3 with sensitivity of 100% and speci-
ﬁcity of 94.7% (p b 0,001). All patients with GBM recurrence had the
value of tCho/tNAA above this cut-off; yet, there were still 5.3% (1/19)
lesion assigned as PsP reaching the same tCho/tNAA cut-off as GBM re-
currence. Another metabolite ratio with statistical signiﬁcance was
tNAA/tCr characterized by the threshold ≤0.7 for calling the GBM recur-
rencewith sensitivity of 96.6% and speciﬁcity of 94.7% (p b 0,001). There
were 93.2% (55/59) lesion considered as the GBM recurrence that had
the tNAA/tCr values below the cut-off, just as 5.3% (1/19) as PsP.
The calculated ADCmean values were signiﬁcantly lower in the GBM
relapse group than in the PsP group (p b 0.001), with the cut-off of
1313 × 10−6 mm2/s (sensitivity 98.3% and speciﬁcity 100.0%). Ninety-
eight percent of patients with the GBM relapse had the ADCmean
≤1313 × 10−6 mm2/s while all the patients with PsP had the ADCmean
N1313 × 10−6 mm2/s.3.3. Characteristics of the patients in the validation cohort
The basic characteristics of the patients in the validation cohort are
summarized in Table 1 and are balanced with the study cohort. TheirTable 3
The percentage distribution of patients with the pseudoprogression and glioblastoma re-






tCho/tNAA b1.3 18 (94.7%) 0 b0.001
≥1.3 1 (5.3%) 59 (100.0%)
Median (min; max) 0.74 (0.33–1.77) 2.13 (1.35–9.60) b0.001
tCho/tCr b0.7 11 (57.9%) 15 (25.4%) 0.013
≥0.7 8 (42.1%) 44 (74.6%)
Median (min; max) 0.64 (0.28–1.37) 0.89 (0.44–2.83) 0.013
tNAA/tCr N0.7 18 (94.7%) 4 (6.8%) b0.001
≤0.7 1 (5.3%) 55 (93.2%)
Median (min; max) 0.99 (0.28–1.59) 0.41 (0.11–0.96) b0.001
Lac + Lip 1.3/tCr b1.6 12 (63.2%) 14 (23.7%) 0.004
≥1.6 7 (36.8%) 45 (76.3%)
Median (min; max) 1.13 (0.07–10.65) 2.69 (0.40–15.63) 0.005
Lac + Lip 0.9–1.3/tCr b2.0 13 (68.4%) 13 (22.0%) b0.001
≥2.0 6 (31.6%) 46 (78.0%)
Median (min; max) 1.33 (0.08–12.35) 3.26 (0.54–17.42) 0.004
ADCmean N1313 19 (100.0%) 1 (1.7%) b0.001
≤1313 0 58 (98.3%)
Median (min; max) 1372 (1317–1476) 1155(756–1344) b0.001pertinent metabolite concentrations and ADCmean values are reported
in Table 4 together with the level of success in the prediction of diagno-
sis by eachmeasured characteristic. The tCho/tNAA ratio assigned diag-
nosis correctly in 15/16 (94%) patients, the ADCmean value in 15/16
(94%) patients, the concentration ratio of tNAA/tCr in 13/16 (81%) pa-
tients, while tCho/tCr, Lac + Lip 1.3/tCr and Lac + Lip 0.9–1.3/tCr only
in 8/16 (50%) patients. These results conﬁrm expected speciﬁcity for
the measured MR characteristics. The combination of tCho/tNAA and
ADCmean led to the highest accuracy while establishing the ﬁnal
diagnosis.
4. Discussion
The accurate and timely identiﬁcation of a tumor relapse is themost
essential prerequisite of an efﬁcient salvage therapy emphasizing the
importance of precise assessment of the response to the initial treat-
ment. Well-known difﬁculties with distinguishing between a GBM re-
currence and treatment related changes caused by the administration
of concomitant RT and TMZ (pseudoprogression) or angiogenesis inhib-
itors (pseudoresponse) (Hygino da Cruz et al., 2011; Chakravarti et al.,
2006) are already expressed in the current RANO (Response Assess-
ment in Neuro-Oncology) criteria (Wen et al., 2010). Nevertheless, the
evolution of the response criteria that is a continuingprocess and imple-
mentation of advanced MRI methods is expected, most likely by MRS
andDWI because of their high availability. Especially for these advanced
MRImethods, the standardization ofMRI protocols is needed in order to
be used optimally in the evaluation of results frommulticentric studies.
The topicality of this need is expressed by the current consensual rec-
ommendations for the standard brain tumor imaging protocol in clinical
trials published in September 2015, which already include pre-contrast,
axial 2D, 3-directional DWI (Ellingson et al., 2015). Before similar rec-
ommendations for other advanced MRI modalities are established, cen-
ters utilizing thesemethods to resolve ambiguous ﬁndings in the classic
structural MRI should develop their own thresholds and cut-offs for a
valid image description.
The MRS seems to be a promising method that is complementary to
thewidely used structuralMRI and can be used to increase the diagnos-
tic accuracy of the brain tumor imaging protocol. The results of this
study proved very high sensitivity and speciﬁcity of the tCho/tNAA con-
centration ratio (100.0% and 94.7%, respectively) for a non-invasive dif-
ferentiation between a GBM recurrence and PsP. The underlying
pathophysiology of the MRS observations is well described especially
from the experience with glioma grading (Bulik et al., 2013). Choline
represents the marker of cell membrane integrity and turnover and is
associated with the presence of an increased tumor cell proliferation,
while NAA is the marker of the density and viability of neurons. Thus,
their mutual ratio forms the best approach when using the MRS for
brain tumor diagnostics. The result of the MRS, though, depends on
the type of the MR scanner, speciﬁc acquisition setup parameters, and
is very sensitive to the proximity of FOV to the surrounding structures
decreasing signal/noise ratio of the brain spectra (i.e. bone). As the spec-
trumquality is also highly inﬂuenced by the personal experience of a ra-
diologist, it is useful to establish an institutional protocol with the
adjustment of thresholds and cut-offs for the main metabolite concen-
trations measured by the MRS. Moreover, there is the signiﬁcant
Fig. 1. The pseudoprogression and glioblastoma recurrenceﬁndings onMRI. RepresentativeMRI examples of the pseudoprogression (A–E) and glioblastoma relapse (F–J): (A)+ (G) show
T1WI, (B)+ (H) show T1WI with gadolinium, (C)+ (I) show T2WI, (D)+ (J) show the ADCmapswithmarked VOI and corresponding ADCmean values, and (E)+ (F) show the proton
MR spectroscopy maps focused on tCho/tNAA concentration ratio with marked VOI, corresponding values and spectra. The MR spectra illustrate concentrations of the main metabolites
within the selected voxel. The color scale for the tCho/tNAA ratio corresponds to the color map shown for theMRSI grids overlaid on top of theMR images. The signal-to-noise ratio of the
presented MR spectra is 4.98 in pseudoprogression and 4.86 in glioblastoma recurrence as well as the error of tCho/tNAA concentration 7% and 4%, respectively.
319T. Kazda et al. / NeuroImage: Clinical 11 (2016) 316–321heterogeneity of glial tumor tissue andmany suspected recurrences are
localized in close proximity to the bone increasing noise in the acquired
MR spectra. Thus, it is useful to perform theMRS bymeans of a Spectro-
scopic Imaging technique in two orthogonal planes coveringmost of the
enhancing brain regions. We faced all the described difﬁculties in MRS
voxel analysis since the patients of our cohort underwent gross total re-
section (GTR). This patients' selection was needed, whether we wanted
to analyze the ability of MRS and ADC maps to distinguish strictly be-
tween the pseudoprogression and tumor recurrence with no bias by a
residual tumor. The probability to achieve GTR is higher in the case of
small and superﬁcial tumors located in the proximity of the skull. In ad-
dition, the majority of gadolinium-enhancing lesions were heteroge-
neous, irregular in shape, and small due to a frequent follow-up that
further underline necessity to use the Spectroscopic Imaging technique
and strict voxel selection. Compare to our methodology, Single Voxel
MR spectroscopy is often used in published studies but it is highly inﬂu-
enced by the partial volume effect where the obtained spectra are
distorted by surrounding tissue (Lee et al., 2013).
There are several studies focusing on MRS for the purpose of differ-
entiating glioma recurrence from treatment related changes. The cur-
rent meta-analysis by Zhang et al., involving 18 studies and 455
patients, showed only moderate sensitivity and speciﬁcity of the tCho/
tNAA ratio (88% and 86%, respectively) for differentiating a recurrent
glioma from radiation necrosis (Zhang et al., 2014). However, the late
treatment related changes of RT and TMZ have some similar histopath-
ologic features as a high-grade glioma relapse (e.g. the presence of ne-
crosis) that can lead to a decreased accuracy of MRS diagnostic and
can explain our superior results because we observed only patients
with PsP. Moreover, most studies reviewed by Zhang and colleagues
used Single VoxelMRSwhere average values from larger voxels are pro-
duced. The analysis of individual small voxels may also explain higher
sensitivity and speciﬁcity observed in the presented study. Neverthe-
less, as we can expect lower sensitivity and speciﬁcity of the MRS in
the general diagnostic protocol for differential diagnostic in neuro-
oncology,we agreewith the recommendation of Zhang et al. to combine
MRSwith other multimodal imagingmethods. For example, that would
be deﬁnitely the case of the patient number 12 from our validation co-
hort where conﬂicting results of MRS and DWI were presented.Fortunately, this patient was able to undergo biopsy validation
conﬁrming the tumor recurrence. Otherwise, close follow-up with
early repeated imaging studies would be indicated.
Diffusion-weighted imaging describes changes in water diffusivity
mainly as the function of changes in cell density. The diffusion changes
can be quantiﬁed by the ADC. Generally speaking, decreased diffusivity
is the consequence of an enhanced tumor cell proliferation and is
reﬂected by the water diffusion restriction that lowers ADC values. In
the present study, the evaluation of mean ADC values led to the highest
sensitivity and speciﬁcity with the cut-off of 1313 × 10−6 mm2/s in
distinguishing between a GBM recurrence and PsP that was proved in
our validation cohort of patients. For all patients with PsP from this
study cohort, the ADCmean value was N1313 × 10−6 mm2/s. However,
evaluating the diagnostic quality of DWI in differentiating glioma recur-
rence from radiation necrosis, the current meta-analysis by Zhang et al.
from April 2015 pooled and weighted data from 284 patients, and
showed only moderate diagnostic performance in differentiating the
glioma recurrencewith sensitivity of 82% (95% CI: 75,87) and speciﬁcity
of 84% (95% CI: 76,91) (Zhang et al., 2015). In the present study, the
higher sensitivity and speciﬁcity observed can be explained by the
sameway as in the case of theMRSmentioned above— treatment relat-
ed changes represented exclusively by PsP with no case of
radionecrosis.
The lack of radionecrosis in our cohort can be explained by a time
factor. The aim of our study was to describe early MRI changes after on-
cology treatment; however, radionecrosis is more often related to the
late effect of radiotherapy. Regardless of low radionecrosis incidence
in selected group of patients after RT and TMZ (9.3% of patients),
Ruben with co-authors described that mean interval from the comple-
tion of radiotherapy to the diagnosis of radionecrosis was 11.6 months
in the cohort of 426 patients treated for glioma (Ruben et al., 2006).
The lack of radionecrosis may be also related to the gross total extent
of resections and generally less aggressive strategy in delivery of radio-
therapy (normalization to 95% of prescribed dose, strict limitations of
Dmax, less generous target deﬁnition strategy with reference to RTOG
rather than to EORTC approach).
This study has also some inherent limitations. The fact that a biopsy
for proving the ﬁnal diagnosis (recurrence vs. treatment related
Table 4
The validation of the calculated metabolite concentration ratios and ADCmean cut-offs for the GBM recurrence by the respective cohort of patients. The gray color indicates discrepancy
between the predicted value and the real measured value. R — recurrence, PsP — pseudoprogression.
Validation cohort
n = 16 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Final diagnosis
R / PsP R R R R PsP R R R R R R R R PsP PsP PsP
tCho/tNAA
cut–off ≥ 1.3 1.5 2.0 2.4 2.7 1.1 2.7 5.1 3.3 3.6 1.8 5.1 1.2 2.0 0.5 1.0 1.0
tCho/tCr
cut–off ≥ 0.7 0.6 0.7 0.6 0.6 0.4 0.5 0.3 0.5 0.7 0.8 0.8 0.4 0.4 0.5 0.5 0.6
tNAA/tCr
cut–off ≤ 0.7 0.4 0.3 0.2 0.2 0.4 0.2 0.1 0.2 0.2 0.4 0.2 0.4 0.2 1.1 0.6 0.6
Lac +Lip 1.3/tCr
cut–off ≥ 1.6 0.5 1.1 3 0.6 2.2 0.8 1 0.7 1.7 1.4 2.8 0.9 1.7 0.4 0.5 0.4
Lac + Lip 0.9–1.3/tCr
cut–off ≥ 2.0 0.6 1.3 4.7 0.9 3.8 2 1.7 1.1 2.2 1.8 3.4 1.6 2.1 0.7 0.8 0.7
ADCmean
cut–off ≤ 1313
1248 1157 928 1189 1387 1287 1038 917 838 1348 937 1197 1298 1503 1425 1398
320 T. Kazda et al. / NeuroImage: Clinical 11 (2016) 316–321changes) was missing in 33% of patients, as their best interest was
reﬂected, may prevent the deeper explanation of the observedmetabo-
lite concentrations or the ADC data. It may be assumed that some pa-
tients develop the overlapping imaging features of both PsP and early
GBM recurrence at the same time, which lowers the tCho/tNAA ratio
and increases the ADCmean value due to the predominance of initial
PsP changes. On the other hand, patients with PsP are more often
those with a favorable prognosis and the concurrent presence of PsP
and early GBM progression is not a case of all patients with PsP. More-
over, the use of biopsy samplesmay also be difﬁcult to interpret because
of the above mentioned tissuemixture, as well as the post radiotherapy
changes. Itmeans that the single target stereotactic needle biopsy of the
lesion suspected of a tumor recurrence may be inaccurate (Hygino da
Cruz et al., 2011). Patients who are not able to undergo tumor resection
or at least biopsy validationmaymost beneﬁt from the non-invasive na-
ture of advancedMRImethods and, in clinical practice, theymay be can-
didates for further imaging studies including MR perfusion or positron
emission tomography examination. With this consideration, we can
agreewith the recommendation of Zhang et al. to combineDWI imaging
results with other multimodal imaging methods (Zhang et al., 2014,
2015). Thus, combination of ADC values and metabolite concentrations
measured by MRS could produce a single prediction with a signiﬁcant
clinical impact; however, other studies with more patients included
are needed for valid recommendations.5. Conclusion
In conclusion, there is the increasing evidence for routine utilization
of advancedMRImethods such asDWI andMRS in brain tumor imaging
protocols. This study has proved that the combination of ADCmean
values ≤1313 × 10−6 mm2/s and the tCho/tNAA concentration ratio
≥1.3 have the high validity for a non-invasive differentiation between
a GBM recurrence and pseudoprogression. However, institutional deﬁ-
nition and validation of the thresholds of the advanced MR methods is
needed in order to implement the multimodal imaging into routine
clinical practice, as well as clinical trials.Conﬂicts of interest
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